

# Chemotherapy is the First Line Treatment of Cancer with Chemotherapeutic Drug

Ben C. Valdez\*

*Department of Stem Cell Transplantation & Cellular Therapy, University of Texas, USA*

On behalf of the Board of the Chemotherapy: Open Access my co-editors, I am glad to introduce the Volume 08, Issue 2 of the journal. The journal established in 2012 with 5 issues in that year has now published 7 volumes and is running the 8 volume. It is time to have a glance at the journal as truly international and continue to assiduous to help the journal in climbing up the ranking ladder with great number of informative and within scope manuscripts.

Hope this year makes a remarkable spot in the annals of the journal as it includes some very knowledge gaining manuscripts within scope of journal. To get best advantage out of this development, we encourage more types of articles asides, regular research, review or commentary articles. Chemotherapy: Open Access (CMT) deals with various types of therapeutic techniques such as Cytotoxic, Electro, and the antimicrobial chemotherapies used to treat several dreadful diseases, particularly Cancer. It also accepts articles on immune suppressant and its application along with different aspects of chemotherapy research and chemotherapy reviews. This scientific journal includes a wide range of fields in its discipline to create a platform for the authors to make their contribution towards the journal.

Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cells in your body. Chemotherapy is most often used to treat cancer, since cancer cells grow and multiply much more quickly than most cells in the body. Many different chemotherapy

drugs are available. Chemotherapy is one of the best Open Access journals publishes the relevant and reliable information on the discoveries and current developments in the form of original articles, review articles, case reports, short communications, etc. and all other areas of the field and making them freely available online without any restrictions or any other subscriptions to researchers worldwide.

As insights into the molecular pathways governing cell growth and cell death have been gained, so have the identities of specific components regulating those pathways and their promise as targets for cancer therapy. The rationale behind targeting individual components, ideally those uniquely expressed (selectively over-expressed) or heavily relied upon in cancer cells/tumors, is that cytotoxicity will be selective/specific for such cells, thus limiting potentially harmful side effects. Although there is great merit in this line of reasoning, as evidenced by the successes that have been achieved, it may be that this approach is also, in itself, a limitation to drug development. Let us address the question as to which direction(s) research advancing drug development might prove more productive by examining examples of the more successful current therapeutics and their limitations. As such, this note will not be all-inclusive nor is it intended to court favor of one therapeutic over another. It is also noted this will express the view of one researcher who has yet to figure out how cells die.

---

**Correspondence to:** Ben C. Valdez, Associate Professor, Department of Stem Cell Transplantation & Cellular Therapy, University of Texas, USA, E-mail: Valdezbc@gmail.edu

**Received:** M 01, 2021, **Accepted:** M 15, 2021, **Published:** M 22, 2021

**Citation:** Valdez BC (2021) Chemotherapy is the First Line Treatment of Cancer with a Chemotherapeutic Drug. Chemo open access 9:132

**Copyright:** © 2021 Valdez BC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.